1955: Polio Vaccine Results

On This Day in Health: April 12, 1955

On April 12, 1955, Thomas Francis Jr. announced the results of the large field trial of Jonas Salk’s polio vaccine at the University of Michigan. Scientists, physicians and reporters gathered at Rackham Auditorium in Ann Arbor to hear the evaluation. The findings showed that the vaccine could substantially reduce paralytic polio, with protection reported as high as eighty to ninety percent in the relevant comparisons. The announcement transformed a closely watched experiment into evidence for a practical preventive measure. It was a results day, not the moment the vaccine was first conceived or the date polio disappeared. That distinction gives the anniversary its specific place in medical history.

Polio had become a source of widespread fear, particularly for families with young children. Although many infections did not cause paralysis, the severe consequences could be life-changing. Salk’s approach used inactivated poliovirus rather than a live weakened virus. His laboratory work at the University of Pittsburgh was supported by the National Foundation for Infantile Paralysis, the organization associated with the March of Dimes. Earlier studies helped establish that the preparation could stimulate antibodies. The much larger 1954 field trial tested whether that biological response translated into protection against disease in the real world. It involved children, families, health workers and investigators on an unprecedented scale.

The University of Michigan account records more than 1.8 million children in the trial population. The evaluation included areas using vaccine and placebo, as well as areas with observed comparison groups. Francis and his team analyzed cases and outcomes rather than relying on the enthusiasm surrounding the vaccine. That separation between development and independent evaluation was essential to the announcement’s credibility. The results did not promise perfect protection, and different forms of disease and study arrangements required careful interpretation. Nevertheless, the evidence supported a major preventive advance. The scale of participation also revealed how a public health experiment depended on organization, community trust and the cooperation of people far beyond a laboratory.

April 12 became a landmark because strong clinical evidence changed what society could reasonably hope to prevent. Turning those findings into broad protection still required vaccine production, delivery and continuing attention to quality and safety. Success in a field trial did not complete the practical work of immunization. The longer story of polio prevention would include other vaccines and sustained vaccination efforts. The anniversary’s enduring lesson is the power of a well-evaluated preventive intervention, backed by public participation and scientific scrutiny. Salk’s vaccine helped change the relationship between families and a feared disease, while the Francis evaluation demonstrated why the decisive moment was not simply a discovery, but a carefully tested result.